WO2001051090A3 - Matrices polymeriques amphiphiles et ioniques et derives de telles matrices - Google Patents

Matrices polymeriques amphiphiles et ioniques et derives de telles matrices Download PDF

Info

Publication number
WO2001051090A3
WO2001051090A3 PCT/FR2001/000064 FR0100064W WO0151090A3 WO 2001051090 A3 WO2001051090 A3 WO 2001051090A3 FR 0100064 W FR0100064 W FR 0100064W WO 0151090 A3 WO0151090 A3 WO 0151090A3
Authority
WO
WIPO (PCT)
Prior art keywords
amphilic
ionic polymer
derivatives
polymer matrixes
matrixes
Prior art date
Application number
PCT/FR2001/000064
Other languages
English (en)
Other versions
WO2001051090A2 (fr
Inventor
Miguel Ignacio De
Laurent Imbertie
Didier Betbeder
Francois Lescure
Roger Kravtzoff
Original Assignee
Biovector Therapeutics Sa
Miguel Ignacio De
Laurent Imbertie
Didier Betbeder
Francois Lescure
Roger Kravtzoff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0000329A external-priority patent/FR2803526A1/fr
Application filed by Biovector Therapeutics Sa, Miguel Ignacio De, Laurent Imbertie, Didier Betbeder, Francois Lescure, Roger Kravtzoff filed Critical Biovector Therapeutics Sa
Priority to AU2001231865A priority Critical patent/AU2001231865A1/en
Publication of WO2001051090A2 publication Critical patent/WO2001051090A2/fr
Publication of WO2001051090A3 publication Critical patent/WO2001051090A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/54—Polymers characterized by specific structures/properties
    • A61K2800/542—Polymers characterized by specific structures/properties characterized by the charge
    • A61K2800/5426—Polymers characterized by specific structures/properties characterized by the charge cationic

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Birds (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un nouveau type de matrices polymériques amphiphiles et ioniques comportant une matrice hydrophile macromoléculaire portant une charge ionique positive ou négative et dans laquelle est incorporée une phase lipidique de signe contraire à celui de la matrice. L'invention se rapporte également à leur méthode de fabrication et leur utilisation.
PCT/FR2001/000064 2000-01-12 2001-01-10 Matrices polymeriques amphiphiles et ioniques et derives de telles matrices WO2001051090A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001231865A AU2001231865A1 (en) 2000-01-12 2001-01-10 Amphilic and ionic polymer matrixes and derivatives thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR00/00329 2000-01-12
FR0000329A FR2803526A1 (fr) 2000-01-12 2000-01-12 Matrices polymeriques amphiphiles et ioniques et derives de telles matrices
FR00/15126 2000-11-23
FR0015126A FR2803517A1 (fr) 2000-01-12 2000-11-23 Matrices plymeriques amphiphiles et ioniques et derives de telles matrices

Publications (2)

Publication Number Publication Date
WO2001051090A2 WO2001051090A2 (fr) 2001-07-19
WO2001051090A3 true WO2001051090A3 (fr) 2002-02-28

Family

ID=26212087

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/000064 WO2001051090A2 (fr) 2000-01-12 2001-01-10 Matrices polymeriques amphiphiles et ioniques et derives de telles matrices

Country Status (3)

Country Link
AU (1) AU2001231865A1 (fr)
FR (1) FR2803517A1 (fr)
WO (1) WO2001051090A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0418828A (pt) * 2004-06-16 2007-11-13 Cargill Inc produtos de amido ceroso reticulado catiÈnico, um método para produzir os produtos de amido, e o uso em produtos de papel
FR2982262A1 (fr) 2011-11-03 2013-05-10 Univ De Droit Et De La Sante De Lille 2 Nanoparticule comportant un coeur charge en phospholipide et une proteine adsorbee sur ledit coeur-utilisation pour la delivrance d'une proteine dans une cellule

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757768A1 (fr) * 1996-12-27 1998-07-03 Biovector Therapeutics Sa Vecteur particulaire homeocharge et composition pharmaceutique ou cosmetique le contenant
WO1998056334A1 (fr) * 1997-06-13 1998-12-17 University Of Nebraska Board Of Regents Compositions diffusant des agents biologiques et leurs procedes de preparation
FR2766706A1 (fr) * 1997-07-30 1999-02-05 Biovector Therapeutics Sa Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757768A1 (fr) * 1996-12-27 1998-07-03 Biovector Therapeutics Sa Vecteur particulaire homeocharge et composition pharmaceutique ou cosmetique le contenant
WO1998056334A1 (fr) * 1997-06-13 1998-12-17 University Of Nebraska Board Of Regents Compositions diffusant des agents biologiques et leurs procedes de preparation
FR2766706A1 (fr) * 1997-07-30 1999-02-05 Biovector Therapeutics Sa Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEE ROBERT J ET AL: "Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 14, 1996, pages 8481 - 8487, XP002016042, ISSN: 0021-9258 *
MAJOR M ET AL: "Characterisation and phase behaviour of phospholipid bilayers adsorbed on spherical polysaccharidic nanoparticles.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1327, no. 1, 1997, pages 32 - 40, XP000938309, ISSN: 0006-3002 *

Also Published As

Publication number Publication date
AU2001231865A1 (en) 2001-07-24
FR2803517A1 (fr) 2001-07-13
WO2001051090A2 (fr) 2001-07-19

Similar Documents

Publication Publication Date Title
EP0950402A3 (fr) Composition pharmaceutique à mâcher à matrice de gélatine
AU2003282100A1 (en) Process for dissolving lipophilic compounds, and cosmetic composition
CA2362233A1 (fr) Procede de reticulation d'acide hyaluronique avec des polymeres
CA2399039A1 (fr) Gel de l'acide hyaluronique, son procede de production et produit medical le contenant
CA2335270A1 (fr) Milieu electrochromique avec stabilite amelioree de la concentration, son procede de preparation et son utilisation dans des dispositifs electrochromiques
CA2404057A1 (fr) Desinfection d'une surface dure avec une composition comprenant de l'essence de cannelle et/ou l'un de ses actifs
AU7872100A (en) Snapshot restore of application chains and applications
CA2322579A1 (fr) Compositions ophtalmiques gelifiantes, contenant de la gomme de xanthanne
AU7295900A (en) Aqueous gelled composition comprising a block copolymer including at least a water soluble block and a hydrophobic block
WO2001022936A8 (fr) Formulations topiques sous forme de suspension contenant de la ciprofloxacine et de la dexamethasone
IE891798L (en) Novel ó-glucosidase inhibitors
EP0917873A4 (fr) Gouttes oculaires
WO2001012778A3 (fr) Floculation de produit cellulaire
EP1064909A3 (fr) Composition cosmétique à base d'emulsions eau-dans-l'huile à rapport de phase aqueuse élévé
AU2952100A (en) Size composition, method for the production of sized paper or sized cardboard, and sized paper or sized cardboard
EP0507224A3 (fr) Utilisation d'une combinaison de polysaccharides gélifiants et de supports de principe actif finement divises dans des compositions topiques ophtalmologiques
AU2002354205A1 (en) Formulation comprising an ionic compound, a polyionic polymer, a nd a copolymer.
AU5012500A (en) Methods and systems for relieving eye strain
WO1994026263A3 (fr) Utilisation d'un complexe metallique de transition pour le traitement du choc septique
CA2176223A1 (fr) Formulations a base de fenbendazole
CA2147362A1 (fr) Vehicules pharmaceutiques ophtalmiques pour applications topiques
WO2001051090A3 (fr) Matrices polymeriques amphiphiles et ioniques et derives de telles matrices
AU2002246091A1 (en) Electrolyte membrane, membrane electrode units comprising the same, method for the production thereof and specific uses therefor
AU2195800A (en) Bis-amido polybiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions
CA2384492A1 (fr) Protege-dents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP